<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585517</url>
  </required_header>
  <id_info>
    <org_study_id>YMCART201806</org_study_id>
    <nct_id>NCT03585517</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)</brief_title>
  <official_title>Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123
      Chimeric Antigen Receptor to Patients With CD123+ AML
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123
      Chimeric Antigen Receptor to Patients With CD123+ AML and determine the best dosage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 21, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of study related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>IM23 CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM23</intervention_name>
    <description>T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor</description>
    <arm_group_label>IM23 CART</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CD123+ Refractory or Relapsed AML

          -  To be aged 3 to 80 years

          -  Expression of CD123 in Blast ≥90%

          -  ECOG score ≤2

          -  Voluntary participation in the clinical trials and sign the informed consent.

        Exclusion Criteria:

          -  Intracranial hypertension or unconsciousness

          -  Respiratory failure

          -  CD19 negative

          -  Disseminated intravascular coagulation

          -  ALT /AST&gt;3 x normal value; Creatinine&gt; 1.5 x normal value; Bilirubin &gt;2.0 x -normal
             value

          -  Hematosepsis or Uncontrolled active infection

          -  Uncontrolled diabetes

          -  Abalienation;

          -  Patients in pregnancy or breast-feeding period

          -  Previously treatment with any gene therapy products

          -  Any uncontrolled medical disorders that the researchers consider are not eligible to
             participate the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xian lu, PHd</last_name>
    <phone>86</phone>
    <phone_ext>189-1157-6946</phone_ext>
    <email>luxinan@immunochina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xian Lu</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xian lu</last_name>
      <phone>86</phone>
      <phone_ext>86</phone_ext>
      <email>luxinan@immunochina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

